| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/25/2002 | US20020098469 Extracorporeal methods for enhancing antigen presentation and immune responsiveness |
| 07/25/2002 | US20020098253 Oral compositions containing lotus |
| 07/25/2002 | US20020098247 May also include cyclooxygenase inhibitor, mucolytic agent (guaifenesin), and salicin-containing herb which facilitates gastrointestinal tract absorption of chromium |
| 07/25/2002 | US20020098235 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract |
| 07/25/2002 | US20020098210 Formulations and methods for reducing skin irritation |
| 07/25/2002 | US20020098207 Cholesterol sulfate compositions for enhancement of stratum corneum function |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098185 Administering therapeutically effective amount of IL-18 antagonist; treatment of rheumatoid arthritis, inflammatory bowel disease |
| 07/25/2002 | US20020098178 Short term treatment with composition having gastrin/cholecystokinin receptor ligand and EGF receptor ligand, resulting in prolonged period of increased insulin release |
| 07/25/2002 | US20020098175 Hypocholesterolemic agent, hypotriglyceride agent, lipasic and proteasic agents, hypoglycemic agent, hydrocoleretic agent; for ketogenic diet |
| 07/25/2002 | US20020098172 Improved absorption of Coenzyme Q10 into an intestinal tract and to maintain basal blood levels; 30-100 mg/day of coenzyme Q10, polyglycerol oleate and vitamin e |
| 07/25/2002 | US20020098164 Treatment of tumor metastases and cancer |
| 07/25/2002 | US20020098159 Surfactants and organic and/or inorganic acids |
| 07/25/2002 | US20020098112 Celluose acetate coating for sterilization of Trichophyton (fungi), and enteropathogenic Escherichia coli or methicillin tolerant Staphylococcus aureus |
| 07/25/2002 | DE10144711A1 Mixture of microbial lipase, protease and amylase, useful for improving digestion in cases of pancreatic insufficiency |
| 07/25/2002 | DE10102337A1 Preparing ester containing polyunsaturated fatty acids, useful e.g. in animal or human nutrition, by transforming organism with desaturase gene from Phaeodactylum tricornatum |
| 07/25/2002 | DE10101522A1 Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| 07/25/2002 | DE10056059A1 Differenzierung auslösende Substanzen Differentiation-inducing substances |
| 07/25/2002 | CA2443895A1 Differential delivery of nitric oxide |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |
| 07/25/2002 | CA2435374A1 Presbyopia treatment by reducing and preventing lenticular disulfide crosslinks |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2435121A1 Histamine receptor antagonists |
| 07/25/2002 | CA2435081A1 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | CA2434866A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | CA2434736A1 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | CA2434696A1 P27 prevents cellular migration |
| 07/25/2002 | CA2434490A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | CA2434338A1 Pharmaceutical composition having reduced tendency for drug crystallization |
| 07/25/2002 | CA2432800A1 Regulated activation of cell-membrane receptors by metal-chelating agonists |
| 07/25/2002 | CA2431919A1 Ccr5 antagonist and dp-178 polypeptide for treating viral infections |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | CA2426799A1 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 07/25/2002 | CA2425125A1 Method of treating parkinson's disease |
| 07/25/2002 | CA2369212A1 Combination therapy |
| 07/24/2002 | EP1224944A1 Skin immune function controlling agents |
| 07/24/2002 | EP1224942A1 Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| 07/24/2002 | EP1224930A1 Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression |
| 07/24/2002 | EP1224474A1 Multiwell scanner and scanning method |
| 07/24/2002 | EP1224469A1 Method of screening for inhibitors of asp2 |
| 07/24/2002 | EP1224461A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224320A1 Method of screening for inhibitors of asp1 |
| 07/24/2002 | EP1224288A2 Processed human chemokines phc-1 and phc-2 |
| 07/24/2002 | EP1224282A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 07/24/2002 | EP1224268A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 07/24/2002 | EP1224222A2 Chemokine receptor |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224218A1 Dna encoding human alpha1g-c t-type calcium channel |
| 07/24/2002 | EP1224213A2 Complex comprising an igfiie polypeptide-fragment and an igfbp2 polypeptide and its use in the treatment of osteoporosis |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224208A1 Human inwardly rectifying potassium channel subunit |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224199A1 Transgenic mice containing trp gene disruptions |
| 07/24/2002 | EP1224195A1 C-aryl glucoside sglt2 inhibitors |
| 07/24/2002 | EP1224183A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 07/24/2002 | EP1224022A1 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 07/24/2002 | EP1223981A1 Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| 07/24/2002 | EP1223980A2 Use of csf-1 inhibitors |
| 07/24/2002 | EP1223974A2 Medicament in order to induce tolerance |
| 07/24/2002 | EP1223971A2 Compositions and methods for preventing and treating transplant rejection |
| 07/24/2002 | EP1223970A1 Short segments of dap-kinase |
| 07/24/2002 | EP1223969A2 Combined use of a plasminogen activator and il-2 inhibitors for neuroprotection |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223965A2 Modulation of angiogenesis |
| 07/24/2002 | EP1223962A1 Method and compositions for inhibiting adhesion formation |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223952A2 Methods for treatment of solid tumors and metastasis by gene therapy |
| 07/24/2002 | EP1223950A2 Ribozyme therapy for the treatment of proliferative skin and eye diseases |
| 07/24/2002 | EP1223943A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 07/24/2002 | EP1223942A2 Agents for the enhanced oxygen delivery in mammals |
| 07/24/2002 | EP1223938A1 TREATMENT OF MOVEMENT DISORDERS BY ADMINISTRATION OF 5-HYDROXYTRYPTAMINE RECEPTOR/$g(a) 2? ADRENERGIC RECEPTOR ANTAGONIST COMPOSITIONS |
| 07/24/2002 | EP1223937A2 Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| 07/24/2002 | EP1223934A2 Combination therapy including camptothecin |
| 07/24/2002 | EP1223930A1 Treatment of dyskinesia |
| 07/24/2002 | EP1223925A2 Use of a fatty acid derivative for the treatment of external secretion disorders |
| 07/24/2002 | EP1223924A2 Use of csaids in rhinovirus infection |
| 07/24/2002 | EP1223923A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 07/24/2002 | EP1223921A2 Tissue factor antagonists and methods of use thereof |
| 07/24/2002 | EP1223915A1 Dry powder compositions having improved dispersivity |
| 07/24/2002 | EP1223913A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 07/24/2002 | EP0904110B1 Nitric oxide donors capable of reducing toxicity from drugs |
| 07/24/2002 | EP0739210B1 Compositions for local delivery of cytostatic agents |
| 07/24/2002 | CN1360629A Induction of vascular endothelial growth factor (VEGF) by serine/threonine protein kinase AKT |
| 07/24/2002 | CN1360596A Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith |
| 07/24/2002 | CN1360502A Use of dopamine D3 receptor ligands for producing medicaments for treating kidney disorders |
| 07/24/2002 | CN1360497A Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 07/24/2002 | CN1360493A Compositions comprising organosiloxane resins for delivering oral care substances |
| 07/23/2002 | US6423751 Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
| 07/23/2002 | US6423750 Systems for delivering anti-infective compositions to treat disordered tissue such as cold sores |
| 07/23/2002 | US6423747 Cosmetic and dermatological preparations with flavonoids |
| 07/23/2002 | US6423744 Administering an amount of a leukotriene b4 (ltb4) antagonist, preferably a ltb4 receptor antagonistic, to a patient exhibiting adverse drug effect due to exogenous interleukin-2, to decrease the adverse effects |
| 07/23/2002 | US6423743 Analyzing for gene for expression of procyanidin |
| 07/23/2002 | US6423742 Synergistic mixture of limonene and gallic acid |
| 07/23/2002 | US6423738 Administering melatonin |
| 07/23/2002 | US6423705 Combination therapy |
| 07/23/2002 | US6423699 Contraceptives |
| 07/23/2002 | US6423698 Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia |
| 07/23/2002 | US6423687 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 07/23/2002 | US6423683 Microdose therapy |